NAVB Navidea Biopharmaceuticals Inc.

0.7
-0.05  -6%
Previous Close 0.74
Open 0.75
Price To Book -23.24
Market Cap 12,591,018
Shares 18,059,406
Volume 679,360
Short Ratio 7.77
Av. Daily Volume 301,835

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 2b trial is enrolling.
NAV3-31 (TC99m-tilmanocept)
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results
  2. Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock
  3. Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT
  4. Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study
  5. Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock
  6. Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock
  7. Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property
  8. Navidea: 1Q Earnings Snapshot
  9. Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results
  10. Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
  11. Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)
  12. Navidea Biopharmaceuticals Announces Reverse Stock Split
  13. Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates
  14. Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
  15. Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates
  16. Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT
  17. Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  18. Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update
  19. Navidea Biopharmaceuticals Announces Extension of NYSE American Listing
  20. Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court